Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × Standard of Care × Clear all

Phase

Status

Completed 3 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8 Prostatic Neoplasms 6 Lung Neoplasms 5 Hematologic Neoplasms 5 Colorectal Neoplasms 5 Sarcoma 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Anatomic Stage I Breast Cancer AJCC v8 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Smoking 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Head and Neck Carcinoma 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Breast Carcinoma In Situ 2 Xerostomia 1 Urologic Neoplasms 1 Urologic Diseases 1 Triple Negative Breast Neoplasms 1 Tobacco Smoking 1 Smoking Cessation 1 Resectable Colorectal Carcinoma 1 Renal Insufficiency, Chronic 1 Recurrence 1

Interventions

Cyclophosphamide 18 Dexamethasone 17 fludarabine 11 pomalidomide 8 carfilzomib 7 Rituximab 7 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 Lenalidomide 6 Calcium Dobesilate 6 venetoclax 5 Gemcitabine 5 Cisplatin 5 Bortezomib 5 Nivolumab 4 Etoposide 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cemiplimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05704829 2025-11-19

ADAPTHER2-IV

West German Study Group

Phase 2 Active not recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡